Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Services

    Services

    Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read More
    Services
    Adaptive TrialsClinical Research ServicesConsultingEarly PhaseFunctional Services ProvisionLaboratoriesLanguage ServicesMedical ImagingReal World IntelligenceSite & Patient Solutions Value Access Outcomes
    Clinical trials during COVID-19.
    COVID-19 clinical operations

    Clinical trials during COVID-19.

    Bringing the clinical trial to the patient with innovation and in-home solutions.
    Decentralised & hybrid clinical solutions

    Bringing the clinical trial to the patient with innovation and in-home solutions.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read More
    Sectors
    BiosimilarsBiotechGovernment & Public Health SolutionsMedical DevicePharmaceuticals
    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
    The IVDR journey

    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.

    Serving governments, multinational public health organisations, and global NGOs.
    Government and Public Health Solutions

    Serving governments, multinational public health organisations, and global NGOs.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read More
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOncologyRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. We are currently working on a number of COVID-19 vaccine trials.
    Vaccines

    ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. We are currently working on a number of COVID-19 vaccine trials.

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Innovation

    Innovation

    We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

    Read More
    Innovation
    FIRECRESTSafety Reporting SolutionOne SearchEvidence PlatformFLEX ADVANTAGE Medical Imaging TechnologyNONMEM ICONIKPDx-POPPubsHubSIMS
    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
    FIRECREST

    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.

    Connecting patients with the right trial in the right location.
    Patient Engagement Platform

    Connecting patients with the right trial in the right location.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read More
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTherapeutics insightsTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Aggregated news on COVID-19 clinical trials.
    Coronavirus Observatory

    Aggregated news on COVID-19 clinical trials.

    Patient focused research for better outcomes.
    Decentralised & hybrid clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read More
    News & Events
    Press ReleasesIn the NewsMediakitAwardsEventsWebinarsSocial Media
    Creating a world leader in healthcare intelligence and clinical research.
    ICON to acquire PRA Health Sciences

    Creating a world leader in healthcare intelligence and clinical research.

    8 April, 2021
    Webinar: Transforming CNS drug development with wet lab and imaging biomarker solutions

    8 April, 2021

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read More
    About ICON
    Company HistoryICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON is committed to making a positive impact on our people, environment and our community.
    Environmental, Social & Governance

    ICON is committed to making a positive impact on our people, environment and our community.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • EN | 日本語
  1. Home
  2. News & Events
  3. In the News
  4. Constant Vigilance

Constant Vigilance

  • 1 March 2018

Strategies to Mitigate Risks

Tony Clarke outlines how safe design and proactive risk management throughout product lifecycles can mitigate medical and financial risks in this article, taken from pages 84-87 of European Biopharmaceutical Review - Winter 2018 (January) - Samedan Ltd.

Download Article
In this section
In this section
  • Press Releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON Spokespeople
  • Awards
  • Events
    • Industry Events
    • Webinars
    • Workshops
  • Webinars
  • Social Media
  • ICON to acquire PRA Health Sciences
  • Webinar: Transforming CNS drug development with wet lab and imaging biomarker solutions

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

Related Information

Media Article

Constant Vigilance - European Biopharmaceutical Review

Media Article

Constant Vigilance - European Biopharmaceutical Review

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Services
  • Insights
  • Innovation
  • Content Preferences
ICON For
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press Releases
  • Mediakit
  • Events
  • Social Media Dashboard
  • Coronavirus Observatory
  • LinkedIn
  • Twitter
  • Facebook
  • Youtube
  • © 2021 ICON plc
  • Disclaimer
  • Privacy
  • Site Cookies

Connect with us

Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media